Terns Pharmaceuticals

Representative image of a leukemia drug development and biopharma acquisition theme, illustrating why Merck’s $6.7bn Terns Pharmaceuticals deal and TERN-701 are drawing attention as the Keytruda patent cliff approaches.

Pharma Industry News

Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears

Merck agrees to acquire Terns Pharmaceuticals for $6.7B, adding TERN-701 CML drug to its oncology pipeline ahead of Keytruda's 2028 patent cliff. Read the full analysis.

bySrinath

March 26, 2026

Pharma Industry News

Terns Pharmaceuticals faces market pressure following stock offering announcement

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing small-molecule product candidates for serious diseases such as oncology and…

byPallavi Madhiraju

September 11, 2024

Pharma Industry News

TERN-201 NASH clinical trial : Terns reports positive results for phase 1 study

TERN-201 NASH clinical trial : Terns Pharmaceuticals said that an ongoing phase 1 trial of its semicarbazide-sensitive amine…

bypharmanewsdaily

January 12, 2020

The Latest

Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?

Strait of Hormuz reopens on paper, yet ships turn back as Iran and US clash over blockade terms

TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record

Antofagasta (LSE: ANTO) surges 5% as Q1 output beats consensus and Centinela build holds schedule

Merck’s $6.7bn Terns Pharmaceuticals buy puts CML drug TERN-701 in play as Keytruda patent cliff nears

Terns Pharmaceuticals faces market pressure following stock offering announcement

TERN-201 NASH clinical trial : Terns reports positive results for phase 1 study

Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?

Strait of Hormuz reopens on paper, yet ships turn back as Iran and US clash over blockade terms

TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record

Antofagasta (LSE: ANTO) surges 5% as Q1 output beats consensus and Centinela build holds schedule

Shubman Gill’s 86 steers Gujarat Titans past Kolkata Knight Riders in IPL 2026

Kizik launches Freedom Run as it pushes hands-free footwear into the performance running market

Can Terex Corporation (NYSE: TEX) keep climbing into May 1 earnings?

Why eftilagimod alfa’s soft tissue sarcoma data now matters more than ever for Immutep Limited